Potential of the Blue Calm® food supplement in the treatment of alcohol withdrawal-induced anxiety in adult zebrafish (Danio rerio)
Copyright © 2024 Elsevier Ltd. All rights reserved..
Alcohol use disorder (AUD) is characterized by a set of behavioral, cognitive, nutritional, and physiological phenomena derived from the uncontrolled use of alcoholic beverages. There are cases in which AUD is associated with anxiety disorder, and when untreated, it requires careful pharmacotherapy. Blue Calm® (BC) is a food supplement indicated to aid restorative sleep, which has traces of medicinal plant extracts, as well as myo-inositol, magnesium bisglycinate, taurine, and L-tryptophan as its main chemical constituents. In this context, this study aimed to evaluate the potential of the BC in the treatment alcohol withdrawal-induced anxiety in adult zebrafish (aZF). Initially, BC was submitted to antioxidant activity against 2,2-diphenyl-1-picrylhydrazyl radical. Subsequently, the aZF (n = 6/group) were treated with BC (0.1 or 1 or 10 mg/mL; 20 μL; p.o.), and the sedative effect and acute toxicity (96 h) were evaluated. Then, the anxiolytic-like effect and the possible GABAergic mechanism were analyzed through the Light & Dark Test. Finally, BC action was evaluated for treating alcohol withdrawal-induced anxiety in aZF. Molecular docking was performed to evaluate the interaction of the major chemical constituents of BC with the GABAA receptor. BC showed antioxidant potential, a sedative effect, was not toxic, and all doses of BC had an anxiolytic-like effect and showed potential for the treatment of alcohol withdrawal-induced anxiety in aZF. In addition to the anxiolytic action, the main chemical constituents of BC were confirmed in the molecular docking, thus suggesting that BC is an anxiolytic that modulates the GABAergic system and has pharmacological potential for the treatment of alcohol withdrawal-induced anxiety.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:175 |
|---|---|
| Enthalten in: |
Neurochemistry international - 175(2024) vom: 25. Apr., Seite 105706 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Marques, Luzia Débora S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adult zebrafish (Danio rerio) |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.neuint.2024.105706 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369132912 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369132912 | ||
| 003 | DE-627 | ||
| 005 | 20240408232506.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.neuint.2024.105706 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM369132912 | ||
| 035 | |a (NLM)38423391 | ||
| 035 | |a (PII)S0197-0186(24)00033-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Marques, Luzia Débora S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potential of the Blue Calm® food supplement in the treatment of alcohol withdrawal-induced anxiety in adult zebrafish (Danio rerio) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Alcohol use disorder (AUD) is characterized by a set of behavioral, cognitive, nutritional, and physiological phenomena derived from the uncontrolled use of alcoholic beverages. There are cases in which AUD is associated with anxiety disorder, and when untreated, it requires careful pharmacotherapy. Blue Calm® (BC) is a food supplement indicated to aid restorative sleep, which has traces of medicinal plant extracts, as well as myo-inositol, magnesium bisglycinate, taurine, and L-tryptophan as its main chemical constituents. In this context, this study aimed to evaluate the potential of the BC in the treatment alcohol withdrawal-induced anxiety in adult zebrafish (aZF). Initially, BC was submitted to antioxidant activity against 2,2-diphenyl-1-picrylhydrazyl radical. Subsequently, the aZF (n = 6/group) were treated with BC (0.1 or 1 or 10 mg/mL; 20 μL; p.o.), and the sedative effect and acute toxicity (96 h) were evaluated. Then, the anxiolytic-like effect and the possible GABAergic mechanism were analyzed through the Light & Dark Test. Finally, BC action was evaluated for treating alcohol withdrawal-induced anxiety in aZF. Molecular docking was performed to evaluate the interaction of the major chemical constituents of BC with the GABAA receptor. BC showed antioxidant potential, a sedative effect, was not toxic, and all doses of BC had an anxiolytic-like effect and showed potential for the treatment of alcohol withdrawal-induced anxiety in aZF. In addition to the anxiolytic action, the main chemical constituents of BC were confirmed in the molecular docking, thus suggesting that BC is an anxiolytic that modulates the GABAergic system and has pharmacological potential for the treatment of alcohol withdrawal-induced anxiety | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adult zebrafish (Danio rerio) | |
| 650 | 4 | |a Alcohol withdrawal | |
| 650 | 4 | |a Anxiety | |
| 650 | 4 | |a Blue Calm® | |
| 650 | 4 | |a Food supplement | |
| 650 | 4 | |a Gabaergic system | |
| 650 | 7 | |a Anti-Anxiety Agents |2 NLM | |
| 650 | 7 | |a Receptors, GABA-A |2 NLM | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Hypnotics and Sedatives |2 NLM | |
| 700 | 1 | |a Rocha, Yatagan M da |e verfasserin |4 aut | |
| 700 | 1 | |a Nascimento, Gabriela A do |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Sacha Aubrey A R |e verfasserin |4 aut | |
| 700 | 1 | |a Vieira, Natália Chaves G |e verfasserin |4 aut | |
| 700 | 1 | |a Moura, Luiz Francisco Wemmenson G |e verfasserin |4 aut | |
| 700 | 1 | |a Alves, Daniela R |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Wildson Max B da |e verfasserin |4 aut | |
| 700 | 1 | |a de Morais, Selene Maia |e verfasserin |4 aut | |
| 700 | 1 | |a de Oliveira, Keciany A |e verfasserin |4 aut | |
| 700 | 1 | |a da Silva, Larissa Morais R |e verfasserin |4 aut | |
| 700 | 1 | |a Sousa, Kalina Kelma O de |e verfasserin |4 aut | |
| 700 | 1 | |a Vieira-Neto, Antonio Eufrásio |e verfasserin |4 aut | |
| 700 | 1 | |a Coutinho, Henrique Douglas Melo |e verfasserin |4 aut | |
| 700 | 1 | |a Campos, Adriana Rolim |e verfasserin |4 aut | |
| 700 | 1 | |a Magalhães, Francisco Ernani Alves |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurochemistry international |d 1980 |g 175(2024) vom: 25. Apr., Seite 105706 |w (DE-627)NLM012652016 |x 1872-9754 |7 nnns |
| 773 | 1 | 8 | |g volume:175 |g year:2024 |g day:25 |g month:04 |g pages:105706 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.neuint.2024.105706 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 175 |j 2024 |b 25 |c 04 |h 105706 | ||